Derek Oien

Derek Oien is a Senior Scientist in Hematological Cancers at AstraZeneca, where since November 2019, Derek has contributed significantly to research on drug interactions and mechanisms in lymphoma. Previously, as a Postdoctoral Fellow at the Mayo Clinic, Oien discovered a repurposed drug targeting tumors with NF2 mutations in mesothelioma and uncovered treatment vulnerabilities in ovarian cancer. Additional postdoctoral positions included research on AXL inhibition at The University of New Mexico and studies on oxidative stress at the University of Kansas Medical Center. Oien also has a background in drug metabolism from XenoTech, LLC, and experience in team management and regulatory compliance from Boehringer Ingelheim. Oien holds a Ph.D. in Pharmacology and Toxicology from The University of Kansas and a B.S. in Chemistry from the University of Wisconsin-Superior.